GlassScriptPhysician profile
Matei P Socoteanu
NPI 1629269774
$3,235.40
in general payments reported to CMS, 2019-2025
35 companies · $872 in 2025
The $872 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $24.28 · 2022: $346 · 2023: $921 · 2024: $1,071 · 2025: $872.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,566 · Long Term Medical Supply Or Device Loan: $299.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,565.97 |
| Long Term Medical Supply Or Device Loan | $299.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $658.46 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $457.41 | 2022-2025 | Imjudo, Imfinzi, Enhertu |
| Janssen Biotech, INC. | $168.88 | 2022-2025 | Tecvayli, Balversa, Erleada |
| Glaxosmithkline, LLC. | $160.10 | 2021-2025 | Ojjaara, Zejula, Jemperli |
| Merck Sharp & Dohme LLC | $157.64 | 2023-2025 | Keytruda, Lynparza, Welireg |
| Aveo Pharmaceuticals, INC. | $156.88 | 2022-2025 | Fotivda |
| Pfizer INC. | $146.13 | 2022-2025 | |
| Incyte Corporation | $139.95 | 2024-2025 | Monjuvi, Jakafi, Pemazyre |
| E.R. Squibb & Sons, L.L.C. | $127.47 | 2023-2025 | Opdivo |
| Tempus Ai, INC | $112.88 | 2024-2025 | Xt Cdx |
| Sobi, INC | $111.06 | 2023-2024 | |
| Eisai INC. | $108.20 | 2024-2025 | |
| Abbvie INC. | $96.74 | 2024-2025 | |
| Daiichi Sankyo INC. | $68.03 | 2023-2024 | Enhertu |
| Regeneron Healthcare Solutions, INC. | $61.00 | 2024-2025 | Libtayo |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $60.31 | 2023-2024 | |
| Lilly USA, LLC | $49.46 | 2024 | Verzenio, Jaypirca, Retevmo |
| Astellas Pharma US INC | $45.09 | 2023-2025 | Vyloy, Xospata |
| Mirati Therapeutics, INC. | $44.38 | 2023-2024 | Krazati |
| Jazz Pharmaceuticals INC. | $41.97 | 2023-2024 | |
| Cti Biopharma Corp. | $41.17 | 2022-2023 | Vonjo |
| Seagen INC. | $32.49 | 2023 | Padcev |
| Blueprint Medicines Corporation | $27.11 | 2022-2023 | Ayvakit |
| Stemline Therapeutics INC. | $23.72 | 2023 | Orserdu |
| Emd Serono, INC. | $21.29 | 2023 | Bavencio |
| Genmab U.S., INC. | $20.02 | 2023 | Tivdak |
| Adc Therapeutics America, INC. | $19.97 | 2024 | |
| Celgene Corporation | $19.14 | 2025 | Reblozyl |
| Alnylam Pharmaceuticals INC. | $17.25 | 2023 | Oxlumo |
| Sun Pharmaceutical Industries INC. | $14.87 | 2023 | Odomzo, Yonsa |
| Exelixis INC. | $14.41 | 2025 | Cabometyx |
| Gilead Sciences, INC. | $11.92 | 2021 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matei Socoteanu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.